ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1438

Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study

Toshihisa Kojima1, Shuji Asai 1, Masahiro Hanabayashi 2, Masatoshi Hayashi 3, Nobunori Takahashi 1, Yachiyo Kuwatsuka 4, Masahiko Ando 4 and Naoki Ishiguro 1, 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Ichinomiya Municipal Hospital, Ichinomiya, Japan, 3Hayashi Orthopedic Clinic, Nagano, Japan, 4Nagoya University Hospital, Nagoya, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: methotrexate (MTX) and clinical trials, rheumatoid arthritis, Tocilizumab, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Biological DMARD (bDMARD) concomitant with methotrexate (MTX) has made great progress in the treatment of rheumatoid arthritis (RA) in these decades. There are various issues relating to safety, efficacy and economics in clinical practice during long-term therapy.  Some patients discontinue MTX due to toxicity including gastrointestinal (GI) disorders. Thus, de-escalation of MTX during treatment with bDMARD while maintaining a favourable disease activity state may be beneficial treatment option from the perspective of reducing adverse events. The efficacy of tocilizumab (TCZ) has been demonstrated in monotherapy as well as with concomitant MTX, opening up the possibility of MTX discontinuation in these patients if disease control can be maintained.

This study aimed to evaluate the efficacy and safety of MTX discontinuation in RA patients with sustained low disease activity undergoing combination therapy with TCZ plus MTX.

 

Methods: This multicentre, open-label, uncontrolled, prospective 64-week study included RA patients maintaining low disease activity (Clinical Disease Activity Index [CDAI] ≤10) for ≥12 weeks with TCZ plus MTX. MTX was discontinued following 12 weeks of biweekly administration while continuing TCZ therapy. The rescue treatments were performed if the CDAI score was >10 and at the discretion of the investigator and/or upon patient request. The primary endpoint was the proportion of patients maintaining low disease activity with no flare at week 36 (24 weeks after MTX discontinuation). Disease flare was defined as a CDAI score >10 or intervention with the rescue treatments for any reasons. Assuming that 80% of patients would maintain low disease activity at week 36, 43 patients were calculated as necessary to prove the clinical feasibility of discontinuing MTX at a power of ≥80% with a threshold response rate of 60%. Secondary endpoints were GI symptoms (Frequency Scale for Symptoms of Gastro-oesophageal reflux disease score), physical function (HAQ-DI), and quality of life(EQ-5D).

Results: A total of 49 patients completed 36 weeks of therapy. Table 1 shows the baseline (week 0) characteristics of patients included in the efficacy analyses. The proportions (95% CI) of patients who maintained low disease activity without a flare at weeks 12, 24, and 36 were 87.8% (75.2 – 95.4%), 81.6% (68.0 – 91.2%), and 75.5% (61.1 – 86.7%), respectively (Fig. 1). The lower limit of the 95% CI at week 36 exceeded the assumed threshold response rate of 60%, demonstrating the clinical feasibility of MTX discontinuation. The prevalence of gastro-oesophageal reflux disease, defined as a Frequency Scale for Symptoms of Gastro-oesophageal reflux disease score ≥8, significantly decreased from week 0 to 12 (27.1% to 18.4%; P = 0.025) (Fig. 2). No significant impairment were observed in the HAQ-DI and EQ-5D from week 0 to 36 (Fig. 3).

Conclusion: Discontinuation of concomitant MTX is clinically feasible for maintaining low disease activity without impairment of physical function and QOL, and may be beneficial from the perspective of reducing GI symptoms in RA patients treated with TCZ.

Conflict of interest

This study was supported by grant from Chugai Pharmaceutical CO.,LTD.


ACR table190516


ACR fig 190517


Disclosure: T. Kojima, AbbVie, 2, 8, Abbvie, 8, Astellas, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Chugai Pahrmaceutical, 2, 8, Chugai Pharmaceutical CO., LTD., 2, 8, Daiichi-Sankyo, 2, 8, Eli Lilly, 2, 8, Janssen, 2, 8, Janssen Pharmaceutical, 8, Lilly, 2, 8, Mitsubishi Tanabe, 2, 8, Novartis, 2, 8, Pfizer, 2, 8, Takeda, 2, 8, Tanabe Mitsubishi Pharma, 8; S. Asai, AbbVie, 8, Abbvie, 8, Astellas, 8, Bristol-Myers Squibb, 8, Chugai, 8, Chugai Pahrmaceutical, 8, Chugai Pharmaceutical CO.,LTD., 8, Daiichi-Sankyo, 8, Eisai, 8, Janssen, 8, Janssen Pharmaceutical, 8, Pfizer, 8, Takeda, 8, Tanabe Mitsubishi Pharma, 8, UCB Japan, 8; M. Hanabayashi, None; M. Hayashi, None; N. Takahashi, AbbVie, 8, Asahi Kasei, 8, Astellas, 8, Bristol-Myers Squibb, 8, Chugai, 8, Chugai Pharmaceutical CO.,LTD., 8, Daiichi-Sankyo, 8, Eisai, 8, Eli Lilly, 8, Janssen, 8, Mitsubishi Tanabe, 8, Ono, 8, Pfizer, 8, Takeda, 8, UCB Japan, 8; Y. Kuwatsuka, None; M. Ando, None; N. Ishiguro, AbbVie, 2, 8, Abbvie, 2, 8, Asahi Kasei, 2, 8, Astellas, 2, 8, Astellas Pharma, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Chugai Pahrmaceutical, 2, 8, Chugai Pharmaceutical CO.,LTD., 2, 8, Daiichi-Sankyo, 2, 8, Eisai, 2, 8, Eli Lilly, 2, 8, Janssen Pharmaceutical, 8, Kaken, 2, 8, Lilly, 8, Medical Corporation Sanjinkai, 2, 5, 8, Medical Corporation Toukoukai, 2, 5, 8, Mitsubishi Tanabe, 2, 8, Ono, 2, 8, Otsuka, 2, 8, Pfizer, 2, 8, Taisho Toyama, 2, 8, Takeda, 2, 8, Tanabe Mitsubishi Pharma, 2, 8, UCB, 8, Zimmer Biomet, 2, 8.

To cite this abstract in AMA style:

Kojima T, Asai S, Hanabayashi M, Hayashi M, Takahashi N, Kuwatsuka Y, Ando M, Ishiguro N. Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/discontinuation-of-concomitant-methotrexate-in-japanese-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-an-interventional-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discontinuation-of-concomitant-methotrexate-in-japanese-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-an-interventional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology